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Abstract
Background: The liver presents a remarkable capacity for regeneration after hepatectomy but the exact mechanisms 
and mediators involved are not yet fully clarified. Erythropoietin (EPO) and Granulocyte-Macrophage Colony 
Stimulating Factor (GM-CSF) have been shown to promote liver regeneration after major hepatectomy.
Aim of this experimental study is to compare the impact of exogenous administration of EPO, GM-CSF, as well as their
combination on the promotion of liver regeneration after major hepatectomy.
Methods: Wistar rats were submitted to 70% major hepatectomy. The animals were assigned to 4 experimental 
groups: a control group (n = 21) that received normal saline, an EPO group (n = 21), that received EPO 500 IU/kg, a GM-
CSF group (n = 21) that received 20 mcg/kg of GM-CSF and a EPO+GMCSF group (n = 21) which received a 
combination of the above. Seven animals of each group were killed on the 1st, 3rd and 7th postoperative day and their 
remnant liver was removed to evaluate liver regeneration by immunochemistry for PCNA and Ki 67.
Results: Our data suggest that EPO and GM-CSF increases liver regeneration following major hepatectomy when 
administered perioperatively. EPO has a more significant effect than GM-CSF (p < 0.01). When administering both, the 
effect of EPO seems to fade as EPO and GM-CSF treated rats have decreased regeneration compared to EPO 
administration alone (p < 0.01).
Conclusion: EPO, GM-CSF and their combination enhance liver regeneration after hepatectomy in rats when 
administered perioperatively. However their combination has a weaker effect on liver regeneration compared to EPO 
alone. Further investigation is needed to assess the exact mechanisms that mediate this finding.
Introduction
Liver has the unique capacity to regain its original and
optimal mass after partial hepatectomy [1]. However the
risk of immediate postoperative hepatic failure, especially
if the procedure is performed in patients with a diseased
liver, still represents a barrier to the extent of hepatec-
tomy that can be attempted. The identification of factors
that enhance liver regeneration and their clinical implica-
tion could reduce the morbidity and mortality associated
with liver surgery.
However, liver regeneration is a complex phenomenon
and the implicated mechanisms are not yet fully under-
stood and clarified. It is well known that mature hepato-
cytes can replicate [1], representing the main mechanism
of hepatocyte production during regeneration, as well as
non-parenchymal cells that are located in the liver [2].
Bone marrow cells may also play a role in the generation
of hepatocytes after liver injury, while it is known that
many cytokines like IL-6 and TNFa and growth factors
like TGFa, EGF and HGF are implicated in different
stages of the regenerative process [3,4].
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In studies that have been performed in the past, eryth-
ropoietin (EPO) has been shown to be produced by the
regenerating liver after partial hepatectomy in rats [5]
and erythropoietic foci have been found 24-72 hours after
subtotal hepatectomy in rats [6]. EPO has been shown to
have a positive effect on liver regeneration after hepatec-
tomy in many studies [7,8]. In addition, EPO has been
found to have a positive effect on liver regeneration after
ischemia and reperfusion injury [9-11].
Granulocyte-Macrophage Colony Stimulating Factor
(GM-CSF) is a cytokine that, besides the proliferation
and differentiation of haemopoietic precursor cells, has
additional effects on the functional properties of mature
cells involved in inflammation and immunity [12]. It also
enhances the functions of mature macrophages that are
induced to secrete various cytokines including IL-6 and
TNF-a, substances known to participate in liver regenera-
tion [13]. GM-CSF has been used in the past, in order to
stimulate liver regeneration following hepatectomy [14].
The combined administration of EPO and GM-CSF
could possibly have a cumulative effect on liver regenera-
tion. As this is an appealing intervention in order to
enhance liver regeneration after hepatectomy, there are
reports suggesting an antagonistic relationship between
the two factors [15,16].
Aim of the present study is to compare the effect of the
administration of EPO and GM-CSF alone or in combi-
nation on the acceleration of liver regeneration in rats
after major hepatectomy.
Materials and methods
Adult male Wistar rats weighing 200-250 gr each were
obtained from the Hellenic Pasteur Institute (Athens,
Greece) after the approval of the study protocol by Are-
taieion Hospital Research Committee and the authority
of the Athens prefecture for experimental protocols.
They had free access to food and water and were kept in
an air-conditioned room at 21°C with a 12-hr/12-hr light-
dark cycle. The animals were fasted for 12 hr before the
procedure and the same care continued in the postopera-
tive period. Care and handling was in accordance with
the National and European guidelines laboratory animal
care.
Eighty four wistar rats were submitted to 70% major
hepatectomy. The animals were assigned to 4 experimen-
tal groups: a control group (n = 21) that received normal
saline, an EPO group (n = 21), that received EPO 500 IU/
kg, a GM-CSF group (n = 21) that received 20 mcg/kg of
GM-CSF and an EPO+GMCSF group (n = 21) which
received a combination of the above. EPO, GM-CSF or
normal saline were administered subcutaneously every
day at 7 am for 8 days before the operation and for 2 days
postoperatively.
For the induction of anesthesia 40 mg/kg ketamine
(Ketalar 10 mg/ml) along with 1 mg/kg of atropine (atro-
pine sulfate 1 mg/ml) were injected intramuscularly.
Moreover, in a different side 5 mg/kg of Midazolam (Dor-
micum 15 mg/3 ml) diluted to 0.4 ml of normal saline
0,9% were also injected in order to maintain long lasting
anesthesia of the animals undergoing liver resection. The
surgery consisted of 70% partial hepatectomy according
to the methods described by Higgins and Anderson [17].
The operations were performed between 9 am and noon.
The resected liver was sampled for immunohistochemi-
c a l  s t u d y  i n  o r d e r  t o  e v a l u a t e  i f  t h e  f a c t o r s  t h a t  w e r e
administered for 8 days before hepatectomy had any
effect on hepatocytes and to serve as self-control. Seven
animals of each group were killed under anaesthesia by
exsanguination on postoperative days 1, 3 and 7. Immedi-
ately after exsanguination the liver was removed for the
study immunohistochemical study of regeneration.
Hepatic regeneration was evaluated by immunohis-
tochemistry for Proliferating Cell Nuclear Antigen
(PCNA) and Ki-67 [18]. Immunostaining of liver speci-
mens was performed by using an anti-PCNA monoclonal
antibody (PC-10, Dakopatts, Glostrup, Denmark). The
three-step immunoperoxidase method using the Strepta-
vidin-Biotin complex (Dakopatts) was performed,
according to a procedure described previously [19]. Ki 67
was stained using a mouse anti-rat Ki-67 antibody (Dako,
Denmark). Tissue sections were inspected at high power
(x400 magnification) by two independent pathologists in
a blind-coded manner. Positive nuclei were counted in 5-
10 randomly chosen fields that approximate 1000 hepato-
cytes per section. The intensity of the staining was evalu-
ated as negative, medium and high, the latter two being
accepted as positive. Data were expressed as the percent-
age of cells that were positively stained.
The weight of the animals the day of surgery and the
day of euthanasia was also recorded.
Statistical Analysis
Data are expressed as mean ± SD. Differences between
groups were analyzed by one-way analysis of variance
(ANOVA), or if the data were not normally distributed by
a Kruskal-Wallis ANOVA on ranks. Differences between
time points of the same group were analyzed with univar-
iate ANOVA. Bonferroni correction was used for post
hoc multiple group comparisons. The level of statistical
significance was defined as p < 0.05.
Results
Preoperatively
EPO pretreatment increased Ki 67 and PCNA expression
preoperatively (p < 0.01). GM-CSF pretreatment as well
as the combination of EPO and GM-CSF increased
PCNA (p < 0.01), but not Ki 67 expression (p < 0.01).Vassiliou et al. World Journal of Surgical Oncology 2010, 8:57
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Postoperative day 1
On postoperative day 1 all rats had increased Ki 67 and
PCNA expression (p < 0.05).
Postoperative day 3
On postoperative day 3 all rats had increased Ki 67 (p <
0.05). PCNA was increased in the EPO and GM-CSF+
EPO groups, while there was no increase in the GM-CSF
group.
Postoperative day 7
One week after hepatectomy, hepatocytes showed
increased expression of PCNA in all groups (p < 0.01),
while Ki-67 was increased only in the EPO treatment
group (p < 0.01).
In all postoperative days, the combination of EPO and
GM-CSF failed to increase PCNA and Ki 67 staining to
the extent that EPO alone did (p < 0.01). Both markers
did not have any difference between the groups treated
with GM-CSF and the combination of EPO and GM-CSF.
In addition both Ki 67 and PCNA expression were signif-
icantly increased in EPO compared to GM-CSF treated
animals in all post-operative days (p < 0.01). The results
are summarized in Figures 1 and 2.
The percentage of postoperative total body weight vari-
ation did not differ significantly between groups as shown
in Figure 3.
During the experiments 11 rats died, either due to hem-
orrhage or by immediate postoperative complications.
These rats were excluded from the study and replaced by
other animals.
Discussion
Liver presents a remarkable capacity for proliferation
after a partial hepatectomy and can precisely regulate its
growth and mass to adjust its size. The exact mechanisms
of stimulation and regulation of hepatic regeneration
remain unclear. It is well known that various cytokines
and growth factors and perhaps cell populations, other
than hepatocytes are involved. Many different substances
have been reported to stimulate liver cell growth in vivo
and in vitro, including a number of known hormones,
serum factors and some small nutrient molecules [1,2,4].
Figure 1 Ki-67 expression. Percentage of Ki-67 expression for each 
experimental group. Data are expressed as mean ± standard deviation. 
* p < 0.05 compared to baseline of the same timepoint. † p < 0.01 com-
pared to baseline of the same timepoint. ‡ p < 0.01 compared to EPO 
group of the same timepoint.  p < 0.01 compared to EPO group of 
the same timepoint.
Figure 2 PCNA expression. Percentage of PCNA expression for each 
experimental group. Data are expressed as mean ± standard deviation. 
* p < 0.05 compared to baseline of the same timepoint. † p < 0.01 com-
pared to baseline of the same timepoint. ‡ p < 0.01 compared to EPO 
group of the same timepoint.  p < 0.01 compared to EPO group of 
the same timepoint.
Figure 3 Body weight. Postoperative variation of total body weight. 
Data are expressed as mean ± standard deviation. * p < 0.05 compared 
to postoperative day 3 of the same group.Vassiliou et al. World Journal of Surgical Oncology 2010, 8:57
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The discovery that EPO and its receptor play a signifi-
cant biological role in tissues outside of the hematopoi-
etic system has provoked significant experimental
interest and fueled the exploration of additional actions
of the hormone [20,21]. It is a member of the class I
cytokines family and is considered a pleiotropic hor-
mone. The EPO-specific receptor has been recognized in
different cells, such as endothelial cells, epicardium, pla-
centa, pancreatic islets, renal cells and defined areas of
the brain [22]. Previous studies suggested that erythro-
poietin (EPO) was produced in rats by the regenerating
liver [6] following partial hepatectomy and erythropoietic
foci have been recognized 24-72 hours after subtotal
hepatectomy in rats [6]. Kupffer cells seem to be the site
of erythropoietin production after hepatectomy [5].
Angiogenesis seems to be a fundamental requirement
for liver regeneration and its regulation. The modulation
of endothelial cell proliferation or apoptosis has been
shown to affect liver regeneration after partial hepatec-
tomy in mice [23]. During liver regeneration the expres-
sion and activity of proapoptotic pathways is inhibited
and after massive liver resection the activation of apopto-
sis is a major cause for failure of regeneration [24].
Recently EPO has been found to inhibit apoptosis after
injury in various organs, like the brain [25], kidney [26]
and the myocardium [27].
GM-CSF is a haematopoietic growth factor that apart
from stimulating the proliferation and differentiation of
myeloid bone marrow progenitor cells, also enhances the
function of mature macrophages that are induced to
secrete various cytokines including IL-6 and TNF-a [13].
It has been found to be a very potent immunostimulating
agent by priming macrophages to produce cytokines, like
TNF-a and IL-6 in blood of healthy humans as well as in
blood of immunosupressed patients with sepsis and after
cardiopulmonary bypass [28]. Within minutes after PH,
Kupffer cells release cytokines, specifically TNF-a and IL-
6 that are substantial for hepatocytes priming and prepa-
ration for replication [3]. Eroglu et al have already shown
that GM-CSF promotes liver regeneration after hepatec-
tomy in normal and cirrhotic livers [14].
The above mentioned experimental evidences
prompted us to compare the effects of the administration
of rhEPO, GM-CSF and their combination on liver regen-
eration following major hepatectomy. Although the effect
of EPO in this setting has already been reported, there are
few data on the effect of GM-CSF. In addition there are
no data on the effect of their combination on liver regen-
eration. These two factors are thought to be mitogens and
their combination should have a cumulative regenerating
effect on the liver. However, Fatouros et al have reported
that their combined administration seems to attenuate
the beneficial role of EPO on intestinal anastomosis heal-
ing, which is similarly a mitotic process [16]. The major
end-point of this study was to investigate if their combi-
nation has a synergistic or antagonistic effect on liver
regeneration after major hepatectomy.
In our study we chose to evaluate the expression of two
proliferation markers -PCNA and Ki 67-, as these have
been shown to peak at different timepoints of the cell
cycle, and their expression could vary depending on the
stage of cellular duplication. They are sensitive markers
of hepatocyte proliferation, which correlate well with the
extent of regeneration [18]. In addition, they are have
already been widely used for the study of liver regenera-
tion and in particular for the study of the effects of EPO
on liver regeneration.
Our study demonstrates that EPO administration had a
positive effect on liver regeneration process after 70%
hepatectomy by augmenting nuclear activity. This effect
is noted even before any "triggering" for regeneration
took place, as rats pre-treated with rhEPO showed
increased expression of both Ki 67 and PCNA before
hepatectomy was performed. This is in accordance with
the literature, as Bockhorn et al have also demonstrated
similar results. They reported that EPO preconditioning
for three days can raise significantly the Ki-67 prolifera-
tion index and liver-to-body weight ratio of the normal
liver [7]. In addition proliferation markers were increased
after hepatectomy until 3 days on rats treated with
rhEPO, similarly to our results [8]. Although the increase
in our study is substantial, it is the result of a prolonged
EPO pretreatment period (8 days). In addition, our
results represent to total amount of hepatocytes stained,
whether the staining was moderate or intense. As Ki 67
antigen is expressed during the whole cell cycle, it is
uncertain whether the moderately stained cells are in the
process of mitosis, or the antigen is still expressed in the
cell after mitosis.
The dose of EPO administered in our study was 500 IU/
kg and was administered subcutaneously. A wide variety
of doses have been used by other authors [7-9,29,30]. We
used the doses used by Fatouros et al in a study trying to
compare the combined effect of EPO and GM-CSF on
colonic anastomoses healing [15,16]. Generally they are
considered low doses in this experimental setting. How-
ever we did not want to use higher doses as they have
been shown to inhibit liver regeneration [29].
In our study, pre-operative GM-CSF administration
resulted in increased hepatocyte proliferation before
hepatectomy, as well as at postoperative days 1 and 7.
Preoperatively only PCNA was over-expressed, and not
Ki 67. This can be explained by the fact that these two
markers of cellular proliferation do not correspond to the
same cell cycle phase, as PCNA concentration seems to
peak at the at the S phase of the cell cycle, while Ki 67
peaks later, during mitosis, in the M phase [18]. Eroglu et
al showed increased hepatocyte proliferation 2 days afterVassiliou et al. World Journal of Surgical Oncology 2010, 8:57
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hepatectomy in rats were GM-CSF was administered.
This effect however faded at the 7th postoperative day.
However in their study GM-CSF was administered
immediately after hepatectomy, while in our study we
pretreated animals for 8 days before hepatectomy and 2
days after [14]. The dose of GM-CSF administered was 20
mcg/kg as used by other authors [16].
On the other hand pretreatment with the combination
of EPO and GM-CSF resulted in a weaker proliferative
response compared with animals that were treated with
EPO alone. Since EPO alone increased nuclear activity, it
would seem logical that the combination group would
have the same results. The fact that this group showed
less nuclear activity than the EPO group, suggests per-
haps a competitive action between the two growth fac-
t o r s .  T h i s  i s  i n  a c c o r d a n c e  w i t h  t h e  f i n d i n g s  o f  o t h e r
studies, where although EPO administration increased
the tensile strength of colonic anastomoses postopera-
tively in rats, the combined administration of EPO and
GM-CSF failed to show the same results [15,16]. Many
possible mechanisms have been proposed in the litera-
ture. GM-CSF may play an antagonistic role on the EPO
receptor as these hemopoietins have a high homology
[31,32]. A competition between EPO and GM-CSF has
been reported in cells of the marrow [33]. In addition, it
has been shown that GM-CSF can modulate EPO effects
in certain leukemic cell line models of hematopoiesis,
modulating events at the transcriptional and signal trans-
duction level, or decreasing mRNA levels of EPO recep-
tor [34]. Finally concentrations of hemopoietins have
been found to play a key role in the final effect on cellular
response [35].
Conclusions
In conclusion our data suggest that EPO and GM-CSF,
when administered perioperatively in hepatectomy are
able to accelerate liver regeneration. This can be added to
the apparent beneficial effect of EPO in reducing blood
transfusions that are associated with increased morbidity
and might be of particular clinical interest in situations
where hepatectomy is expected to result in significant
liver failure and increased mortality. Future research can
focus on the effect of these factors after hepatectomy
when hepatic parenchymal disease coexists, as well as on
the role of autologous transfusion inducing endogenous
EPO production. Finally, the mechanisms involved in the
inhibition of EPO by GM-CSF are the focus of our cur-
rent research.
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